Abstract
The incidence of malignant lymphomas stands at about five new cases per 100 000 persons per year. These include instances both of Hodgkin’s disease (HD) and the heterogeneous group of non-Hodgkin lymphomas (NHL), with a relative frequency of about 1:3. Lymphomas originate from cells of the pul-pal tissue of the lymph nodes. Hodgkin’s lymphomas are characterized by a very small proportion of specific tumor cells (Hodgkin cells, Reed-Sternberg giant cells) surrounded by numerous nonneoplastic cells. This is distinct from the histological picture of NHL, whose pathognomonic cells constitute the main mass of the tumor.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ahmann DL, Kiely JM, Harrison EG et al. (1966) Malignant lymphoma of the spleen: a review of 49 cases in which the diagnosis was made at splenectomy. Cancer 19:461–469
Arita T, Kuramitsu T, Kawamura M et al. (1995) Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 50:1267–1269
Bagley CM, Roth JA, Thomas LB et al. (1972) The liver biopsy in Hodgkin’s disease. Clinicopathologic correlation in 127 patients. Ann Int Med 76:219–225
Bangerter M, Moog F (1998) Role of whole body FDG-PET in predicting relapse in residual masses after treatment of malignant lymphoma. Brit J Hematol 102 (abstr)
Bangerter M, Kotzerke J, Griesshammer M et al. (1999) PET with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma of the chest. Acta Oncol 38:799–804
Bengel FM, Ziegler S, Avril N et al. (1997) Whole body PET in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 24:1091–1098
Braams JW, Pruim J, Freling NJM et al. (1995) Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 36:211–216
Braunstein EM, White SJ (1980) Non-Hodgkin lymphoma of bone. Radiology 135:5963
Bumann D, de Wit M, Beyer W et al. (1998) CT and F-18-FDG-PET in staging of malignant lymphoma. RöFo 168:457–465
Carr R, Barrington SF, Madan B et al. (1998) Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91:3340–3346
Castellino RA (1982) Imaging techniques for staging abdominal Hodgkin’s disease. Cancer Treat Rep 66:697–700
Castellino RA (1992) Diagnostic imaging studies in patients with newly diagnosed Hodgkins disease. Annals of Oncology 3 (Suppl 4):45–47
Castellino RA, Blank N, Hoppe RT et al. (1986) Hodgkin’s disease: contribution of chest CT in the initial staging evaluation. Radiology 160:603–605
Castellino RA, Hoppe R, Blank N et al. (1984) Computed tomography, lymphography, and staging laparatomy: correlations in initial staging of Hodgkin’s disease. AJR 143:37–41
Coller BS, Chabner BA, Gralnick HR et al. (1977) Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphoma: observations on the value of bilateral biopsies. Am J Pathol 3:105–119
De Wit M, Bumann D, Beyer W et al. (1997) Whole-body PET for diagnosis of residual mass in patients with lymphoma. Ann Oncol 8 Suppl 1:57–60
Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H et al. (1995) Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 22:434–442
Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H et al. (1997) Die Positronenemissionstomographie (PET) bei der Diagnostik and Therapieplanung von malignen Lymphomen. Radiologe 37:74–80
Dorfman RE, Alpern MB, Gross BH et al. (1991) Upper abdominal lymph node size determined with CT. Radiology 180:319–322
Edeiken-Monroe B, Edeiken J, Kim E (1990) Radiologic concepts of lymphoma of bone. Radiol Clin North Am 28:841–864
Eichhorn T, Schroeder HG, Glatz H et al. (1987) Histologisch kontrollierter Vergleich von Palpation and Sonographie bei der Diagnose von Halslymphknotenmetastasen. Laryngol Rhinol Otol 66:266–274
Einstein DM, Singer AA, Chilcote WA et al. (1991) Abdominal lymphadenopathy: spectrum of CT findings. RadioGraphics 11:457–472
Ellis ME, Diehl LF, Granger E et al. (1989) Trephine needle bone marrow biopsy in the initial staging of Hodgkin’s disease: sensitivity and specificity of the Ann Arbor staging procedure criteria. Am J Haematol 30:115–120
Ferrant A, Rodhain J, Michaux JL et al. (1975) Detection of skeletal involvement in Hodgkin’s disease: a comparison of radiography, bone scanning, and bone marrow biopsy in 38 patients. Cancer 35:1346–1353
Fishman EK, Kuhlman LE, Jones RJ et al. (1991) CT of lymphoma: spectrum of disease. RadioGraphics 11:647–669
Glatz S, Kotzerke J, Moog F et al. (1996) Vortäuschung eines mediastinalen NonHodgkin-Lymphomrezidivs durch diffuse Thymushyperplasie. RöFo 165:309–310
Gross BH, Glatzer GM, Orringer MB et al. (1988) Bronchogenic carcinoma metastatic to normal-sized nodes: frequency and significance. Radiology 166:71–74
Higashi K, Clavo A, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34:414–419
Hoane BR, Shields AF, Porter BA et al. (1991) Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. Blood 78:728–738
Hoekstra O, Ossenkoppele GJ, Golding R et al. (1993) Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodesoxyglucose scintigraphy. J Nucl Med 34:1706–1710
Hoffman JM, Waskin HA, Hanson MW et al. (1993) FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 34:567–575
Hoh CK, Glaspy J, Rosen P et al. (1997) Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med 38:343–348
Jabour BA, Choi Y, Hoh C et al. (1993) Extracranial head and neck: PET imaging with 2-(F18-)fluoro-2-deoxy-glucose and MR imaging correlation. Radiology 186:2735
Jánoskuti L, Szilvási I, Papp G et al. (1988) Bone scanning and radiography in the evaluation of patients with malignant lymphoma. Fortschr Röntgenstr 149:427–428
Jones DN, McCovage GB, Sostman HD et al. (1996) Monitoring of neoadjuvant therapy response of soft-tissue and muskuloskeletal sarcoma using F-18-FDG. J Nucl Med 37:1438–1444
Kaplan HS (1973) Staging laparatomy and splenectomy in Hodgkin’s disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients. Nat Canc Inst Monogr 36:291–298
Kaplan HS (1980) Hodgkin’s Disease, 2nd ed. Harvard University Press, Cambridge, MA
Kotzerke J, Guhlmann A, Moog F et al. (1998) Role of attenuation correction for FDG-PET in the primary staging of malignant lymphoma. Eur J Nucl Mecl (in press)
Kubota R, Yamada S, Ishiwata K et al. (1992) Intratumoral distribution of fluorine-18fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972–1980
Lapela M, Leskinen S, Minn H et al. (1995) Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 9:3522–3527
Larcos G, Farlow DC, Antico VF et al. (1994) The role of high dose 67-gallium scintigraphy in staging of untreated patients with lymphoma. Aust N Z J Med 29:5–8
Leibenhaut MH, Hoppe RT, Efron B et al. (1989) Prognostic indicators of laparatomy findings in clinical stage III supradiaphragmatic Hodgkin’s disease. J Clin Oncol 7:81–91
Leskinen-Kallio S, Ruotsalainen U, NAgren K et al. (1991) Uptake of carbon-llmethionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study. J Nucl Med 32:1211–1218
Lowe VJ, Hoffman JM, DeLong DM et al. (1994) Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 35:1771–1777
Mansfield C, Fabian C, Jones S et al. (1990) Comparison of lymphangiography and CT scanning in evaluating abdominal disease in stages III and IV Hodgkin’s disease. Cancer 66:2295–2299
McKenna RW, Hernandez JA (1988) Bone marrow in malignant lymphoma. Haematol/Oncol Clin North Am 2:617–635
Moog F, Bangerter M, Diederichs C et al. (1997) Lymphoma: role of whole-body FDG-PET in nodal staging. Radiology 203:795–800
Moog F, Bangerter M, Diederichs C et al. (1998) Detection of extranodal malignant lymphoma with PET using FDG: comparison with computed tomography. Radiology 206:475–481
Moog F, Bangerter M, Kotzerke J et al. (1998) FDG-PET as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603–609
Moog F, Kotzerke J, Reske SN (1999) FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 40:1407–1413
Munker R, Stengel A, Stäbler A et al. (1995) Diagnostic accuracy of US and CT in the staging of Hodgkin’s disease. 76:1460–1466
Newman JS, Francis IR, Kaminski MS et al. (1994) Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-d-glucose: correlation with CT. Radiology 190::111–116
North LB, Fuller LM, Sullivan-Halley JA et al. (1987) Regression of mediastinal Hodgkin’s disease after therapy: evaluation of time interval. Radiology 164:599–602
North LB, Fuller LM (1982) Importance of initial mediastinal adenopathy in Hodgkin’s disease. AJR 138:229–235
O’Doherty MJ, Barrington SF, Campell M et al. (1997) PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 38:1575–1583
Okada J, Yoshikawa K, Imazeki K et al. (1992) Positron emission tomography using fluorine-18-fluorodeoxy-glucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33:325–329
Okada J, Oonishi I, Yoshikawa K et al. (1994) FDG-PET for the evaluation of tumor viability after anticancer therapy. Ann Nucl Med 8:109–113
Orzel J, Sawaf NW, Richardson (1988) Lymphoma of the skeleton: scintigraphic evaluation. AJR 150:1095–1099
Patz EF (1993) Focal pulmonary abnormalities: evaluation with F18-fluorodeoxyglucose PET scanning. Radiology 188:487–490
Pendlebury SC, Koutts J, Boyages J et al. (1994) Hodgkin’s disease: clinical and radiological prognostic factors in a laparatomy series. Australasian Radiology 38:123–126
Pond GD, Castellino RA, Horning S et al. (1989) Non-Hodgkin lymphoma: influence of lymphography, CT, and bone marrow biopsy on staging and management. Radiology 170:159–164
Radford JA, Cowan RA, Flanagan M et al. (1988) The significance of residual mediastinal abnormality on the chest radiography following radiation therapy for Hodgkin’s disease. J Clin Oncol 6:940–946
Reske SN, Guhlmann A, Schirrmeister H et al (1998) PET in the diagnosis of abdominal tumors. Schweiz-Med-Wochenschr 128:96–108
Rodriguez M (1998) CT, MRI, and PET in non-Hodgkin’s lymphoma. Acta Radiol Suppl 417:1–36
Rodriguez M, Rehn S, Ahlström H et al. (1995) Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med 36:1790–1796
Römer W, Hanauske AR, Ziegler S et al. (1998) PET in non-Hodgkin’s lymphoma: assessment of chemotherapy with FDG. Blood 91:4464 4471
Rosenberg SA, Berard CW, Brown BW et al. (1982) National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical use. Cancer 49:2112–2135
Schechter JP, Jones SE, Woolfenden JM et al. (1976) Bone scanning in lymphoma. Cancer 38:1142–1146
Schirrmeister H (1998) Nachweis eines ossären Befalls beim Plasmozytom mit F-18FDG-PET. Nuklearmedizin 37:43–82 (abstr)
Shields AF, Porter BA, Churchley S et al. (1987) The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. J Clin Oncol 5:225–230
Shreve PD, Grossman HB, Gross MD et al. (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-(F-18)fluoro-D-glucose. Radiology 199:751–756
Skillings JR, Bramwell V, Nicholson RL et al. (1991) A prospective study of MRI in lymphoma staging. Cancer 67:1838–1843
Skovsgaard T, Brinckmeyer M, Vesterager L et al. (1982) The liver in Hodgkin’s disease-II. Histopathologic findings. Eur J Cancer Clin Oncol 18:429–435
Specht L (1992) Tumor burden as the main indicator of prognosis in Hodgkin’s disease. Eur J Cancer 12:1982–1985
Taylor IK, Hill AA, Hayes M et al. (1996) Imaging allergen-invoked airway inflammation in atopic asthma with [18F]-fluorodeoxyglucose and positron emission tomography. Lancet 347:937–940
Tesoro-Tess JD, Balzarini L, Ceglia E et al. (1991) Magnetic resonance imaging in the initial staging of Hodgkin’s disease and non-Hodgkin lymphoma. Eur J Rad 12:81–90
Thill R, Neuerburg J, Fabry U et al. (1997) Comparison of findings with F-18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 36:234–239
Vesselle HJ, Miraldi FD (1998) FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radio-Graphics 18:805–823
Villringer K, Jager H, Dichgans M et al. (1995) Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 19:532–536
Wahl RL, Zasadny K, Helvie M et al. (1993) Metabolic monitoring of breast cancer chemohormonotherapy using PET: initial evaluation. J Clin Oncol 11:2101–2107
Weidmann E, Baican B, Hertel A et al. (1999) PET for staging and evaluation of response to treatment in patients with Hodgkin’s disease. Leuc and Lymph 34:545–551
Weissleder R, Elizondo G, Stark DD et al. (1989) The diagnosis of splenic lymphoma by MR imaging: value of supraparamagnetic iron oxide. AJR 152:175–180
Widding A, Smolorz J, Franke M et al. (1989) Bone marrow investigation with technetium-99m microcolloid and magnetic resonance imaging in patients with malignant myelolympho-proliferative diseases. J Nucl Med 15:230–238
Zasadny K, Wahl RL (1993) Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 189:847–850
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Moog, F. (2000). Hodgkin and Non-Hodgkin lymphoma. In: Wieler, H.J., Coleman, R.E. (eds) PET in Clinical Oncology. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57703-1_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-57703-1_20
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-642-63329-4
Online ISBN: 978-3-642-57703-1
eBook Packages: Springer Book Archive